Rapid-infusion rituximab in lymphoma treatment

Authors:

Abstract
Rituximab® (MabThera; Rituxan Roche) is a chimeric human/murine immunoglobulin G1 monoclonal antibody that binds specifically to the B-cell-surface antigen, CD20. Using the combination of CHOP-R leads to significant improvement in the outcome of elderly patients with diffuse large B-cell lymphoma, with significant survival benefits maintained during a 5-year follow-up [1].